MDxHealth SA (NASDAQ:MDXH) Given Average Recommendation of “Hold” by Analysts

MDxHealth SA (NASDAQ:MDXH) has been given a consensus rating of “Hold” by the five research firms that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $2.1667.

Several research firms recently issued reports on MDXH. Wall Street Zen raised MDxHealth to a “sell” rating in a research report on Saturday, August 15th. William Blair cut MDxHealth from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 14th. Lake Street Capital set a $3.00 price target on MDxHealth and gave the company a “buy” rating in a research note on Friday, August 14th. TD Cowen reissued a “buy” rating and issued a $1.50 price objective (down from $7.00) on shares of MDxHealth in a report on Thursday, May 14th. Finally, BTIG Research reduced their price objective on MDxHealth from $4.00 to $2.00 and set a “buy” rating for the company in a research note on Friday, August 21st.

Hedge Funds Weigh In On MDxHealth

A number of institutional investors have recently bought and sold shares of the business. Perkins Capital Management Inc. lifted its stake in MDxHealth by 7.1% during the 1st quarter. Perkins Capital Management Inc. now owns 1,476,441 shares of the company’s stock valued at $3,396,000 after acquiring an additional 97,500 shares during the period. Kennedy Capital Management LLC purchased a new position in shares of MDxHealth during the third quarter worth $1,826,000. FreeGulliver LLC raised its holdings in shares of MDxHealth by 25.7% during the fourth quarter. FreeGulliver LLC now owns 317,894 shares of the company’s stock worth $1,135,000 after purchasing an additional 65,000 shares during the last quarter. Renaissance Technologies LLC lifted its position in MDxHealth by 21.8% during the first quarter. Renaissance Technologies LLC now owns 304,700 shares of the company’s stock valued at $701,000 after purchasing an additional 54,600 shares during the period. Finally, Mink Brook Asset Management LLC lifted its position in MDxHealth by 64.9% during the fourth quarter. Mink Brook Asset Management LLC now owns 263,420 shares of the company’s stock valued at $940,000 after purchasing an additional 103,686 shares during the period.

MDxHealth Trading Down 4.7%

NASDAQ:MDXH opened at $0.71 on Wednesday. MDxHealth has a twelve month low of $0.40 and a twelve month high of $5.33. The company has a market cap of $35.32 million, a PE ratio of -0.99 and a beta of 1.57. The company’s 50 day moving average is $0.55 and its two-hundred day moving average is $1.43.

MDxHealth (NASDAQ:MDXH) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.01. The company had revenue of $27.21 million during the quarter, compared to analysts’ expectations of $26.14 million. As a group, analysts expect that MDxHealth will post -0.49 EPS for the current fiscal year.

MDxHealth Company Profile

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.